|
|||
2015-06-12 16:15:00 CEST 2015-06-12 16:16:06 CEST REGULATED INFORMATION Biotie Therapies - Total number of voting rights and capitalChange in the number of votes relating to Biotie Therapies Corp.'s sharesBiotie Therapies Corp. Stock Exchange Release 12 June, 2015 at 5.15 p.m. Change in the number of votes relating to Biotie Therapies Corp.'s shares The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"), Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie Therapies Holding AG) has conveyed Biotie shares against consideration pursuant to the option programs as follows: May 2015 to date Total (5/2011- Options 5/2015 to date) outstanding 134,749 9,794,865 2,351,053 The conveyance of Biotie shares relates to the option plan of Synosia Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia") acquired by Biotie in February 2011. According to such Synosia share option plan, options have been granted to employees, former directors and consultants. In connection with the completion of the acquisition of Synosia, the option plan was amended so that instead of shares in Synosia an aggregate maximum of 14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued these 14,912,155 shares to its current subsidiary Synosia in connection with the acquisition to be further conveyed to the option holders when they potentially exercise their option rights in accordance with the terms and conditions of the option program. The conveyed shares previously held as Treasury shares have not carried any voting rights. The conveyance does not affect the number of registered shares. After the conveyances the changes are as follows: Increase in number of Total amount of Number of the Total number outstanding shares voting rights Company's share held of registered by the Biotie Group shares 134,749 453,362,483 2,605,691 455,968,174 Turku, 12 June, 2015 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900 e-mail: virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com [HUG#1928170] |
|||
|